These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22849502)

  • 21. Scoring of tumour response after neoadjuvant therapy in resected pancreatic cancer: systematic review.
    van Roessel S; Janssen BV; Soer EC; Fariña Sarasqueta A; Verbeke CS; Luchini C; Brosens LAA; Verheij J; Besselink MG
    Br J Surg; 2021 Mar; 108(2):119-127. PubMed ID: 33711148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study.
    Klompmaker S; van Hilst J; Gerritsen SL; Adham M; Teresa Albiol Quer M; Bassi C; Berrevoet F; Boggi U; Busch OR; Cesaretti M; Dalla Valle R; Darnis B; De Pastena M; Del Chiaro M; Grützmann R; Diener MK; Dumitrascu T; Friess H; Ivanecz A; Karayiannakis A; Fusai GK; Labori KJ; Lombardo C; López-Ben S; Mabrut JY; Niesen W; Pardo F; Perinel J; Popescu I; Roeyen G; Sauvanet A; Prasad R; Sturesson C; Lesurtel M; Kleeff J; Salvia R; Besselink MG;
    Ann Surg Oncol; 2018 May; 25(5):1440-1447. PubMed ID: 29532342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Okano K; Suto H; Oshima M; Maeda E; Yamamoto N; Kakinoki K; Kamada H; Masaki T; Takahashi S; Shibata T; Suzuki Y
    Ann Surg Oncol; 2017 Sep; 24(9):2777-2784. PubMed ID: 28608121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.
    Takahashi S; Kinoshita T; Konishi M; Gotohda N; Kato Y; Kinoshita T; Kobayashi T; Mitsunaga S; Nakachi K; Ikeda M
    J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):567-74. PubMed ID: 21331805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraductal papillary mucinous neoplasm of the pancreas - epidemiology, risk factors, diagnosis, and management.
    Aronsson L; Andersson R; Ansari D
    Scand J Gastroenterol; 2017 Aug; 52(8):803-815. PubMed ID: 28446039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma.
    Tesfaye AA; Philip PA
    Clin Adv Hematol Oncol; 2019 Jan; 17(1):54-63. PubMed ID: 30843899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis and management of pancreatic cancer.
    De La Cruz MS; Young AP; Ruffin MT
    Am Fam Physician; 2014 Apr; 89(8):626-32. PubMed ID: 24784121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma.
    Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Kawasaki Y; Arigami T; Mori S; Kijima Y; Ueno S; Shinchi H; Natsugoe S
    Ann Surg Oncol; 2018 May; 25(5):1432-1439. PubMed ID: 29404819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: A single-center experience with 2,029 patients.
    Shin SH; Kim SC; Song KB; Hwang DW; Lee JH; Park KM; Lee YJ
    Surgery; 2018 Sep; 164(3):432-442. PubMed ID: 29884479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer.
    Eguchi H; Yamada D; Iwagami Y; Gotoh K; Kawamoto K; Wada H; Asaoka T; Noda T; Takeda Y; Tanemura M; Sakai D; Satoh T; Kudo T; Isohashi F; Mori M; Doki Y
    Dig Surg; 2018; 35(1):70-76. PubMed ID: 28482348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
    McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
    Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
    Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with better prognosis.
    Wang H; Zhao Q
    Ann Diagn Pathol; 2012 Oct; 16(5):427. PubMed ID: 22561135
    [No Abstract]   [Full Text] [Related]  

  • 35. Prognostic Relevance of the Timing of Initiating and the Completion of Adjuvant Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma.
    Lee W; Yoon YS; Han HS; Jang JY; Cho JY; Jung W; Kwon W; Choi Y; Kim SW
    World J Surg; 2017 Feb; 41(2):562-573. PubMed ID: 27834017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Tale of Two Cities: Reconsidering Adjuvant Radiation in Pancreatic Cancer Care.
    de Geus SW; Bliss LA; Eskander MF; Ng SC; Vahrmeijer AL; Mahadevan A; Kent TS; Moser AJ; Callery MP; Bonsing BA; Tseng JF
    J Gastrointest Surg; 2016 Jan; 20(1):85-92; discussion 92. PubMed ID: 26427374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant therapy for pancreatic cancer.
    Kleeff J; Friess H; Büchler MW
    Br J Surg; 2007 Mar; 94(3):261-2. PubMed ID: 17315287
    [No Abstract]   [Full Text] [Related]  

  • 38. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival.
    Lee SM; Katz MH; Liu L; Sundar M; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Fleming JB; Rashid A; Wang H
    Am J Surg Pathol; 2016 Dec; 40(12):1653-1660. PubMed ID: 27631521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pancreatoduodenectomy following neoadjuvant chemoradiation therapy in uncinate process pancreatic cancer.
    Kang CM; Choi JY; Seong JS; Song SY; Lee WJ; Kim MJ; Chung JB
    Pancreas; 2012 Apr; 41(3):467-73. PubMed ID: 22158068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic clues and subsequent examinations that detected small pancreatic cancer.
    Kawada N; Uehara H; Katayama K; Takakura R; Ioka T; Tanaka S; Takenaka A; Tomita Y; Ishikawa O
    Hepatogastroenterology; 2012 Sep; 59(118):1665-9. PubMed ID: 22591644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.